Invention Grant
- Patent Title: Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
-
Application No.: US15084192Application Date: 2016-03-29
-
Publication No.: US10195272B2Publication Date: 2019-02-05
- Inventor: Zhengyu Ma
- Applicant: THE NEMOURS FOUNDATION
- Applicant Address: US FL Jacksonville
- Assignee: The Nemours Foundation
- Current Assignee: The Nemours Foundation
- Current Assignee Address: US FL Jacksonville
- Agency: Drinker Biddle & Reath LLP
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K14/725 ; C12N5/0783 ; C07K16/28 ; A61K39/395

Abstract:
A chimeric antigen receptor (CAR) contains a human FcεRIα extracellular domain or a mutant FcεRIα extracellular domain that has a reduced binding affinity for human IgE compared to wild type human FcεRIα extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
Public/Granted literature
Information query